Allarity Therapeutics, Inc.
No SEC Form 4 filings for $ALLR in the last 30 days.
See all $ALLR insider activity →Allarity Therapeutics announced recent patent awards for its DRP technology, securing commercial exclusivity for stenoparib. The company obtained CLIA lab certification for its in-house lab, enabling sole control of the stenoparib-DRP clinical test. An AACR 2026 analysis found higher pretreatment DRP scores linked to longer overall survival in a prior Phase 2 ovarian cohort.
Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SP
Allotera Therapeutics has opened a minimal residual disease (MRD)-positive cohort in its pivotal T-RRex study of Sofi-cel, an off-the-shelf CAR-T cell therapy for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The company aims to evaluate Sofi-cel's potential to achieve MRD-negative remission and improve long-term outcomes. The study is being conducted at 18 clinical sites in the U.S. and Australia.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ALLR (Allarity Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ALLR coverage spans financial news, corporate actions and technology.
Positive regulatory and intellectual‑property milestones could improve market perception of Allarity's oncology pipeline.
Positive clinical‑development news may lift the stock as investors reassess the drug's commercial potential.
The cohort expansion may increase enrollment speed and generate earlier efficacy data, potentially supporting a higher valuation if results are positive.
The new patent strengthens Allarity's IP portfolio, potentially enhancing the commercial value of its stenoparib program.
The SPAC filing could provide significant funding for Allarity's clinical programs and may attract speculative interest in the biotech.
AlphAI scores every news story that mentions ALLR with an AI model for sentiment and relevance, and aggregates insider trades from Allarity Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Allarity Therapeutics announced recent patent awards for its DRP technology, securing commercial exclusivity for stenoparib. The company obtained CLIA lab certification for its in-house lab, enabling sole control of the stenoparib-DRP clinical test. An AACR 2026 analysis found higher pretreatment DRP scores linked to longer overall survival in a prior Phase 2 ovarian cohort.
1 min readAllarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SP
2 min readAllotera Therapeutics has opened a minimal residual disease (MRD)-positive cohort in its pivotal T-RRex study of Sofi-cel, an off-the-shelf CAR-T cell therapy for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The company aims to evaluate Sofi-cel's potential to achieve MRD-negative remission and improve long-term outcomes. The study is being conducted at 18 clinical sites in the U.S. and Australia.
2 min readAllarity Therapeutics (ALLR) received a Japanese patent for its stenoparib DRP companion diagnostic, valid through 2039. The patent covers methods to predict patient response to stenoparib, a drug in Phase 2 trials for ovarian and lung cancers. The company also holds U.S. and European patents for the DRP. ALLR stock closed at $1.17, down 4.10%.
2 min readAllarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company
2 min readAllarity Therapeutics (NASDAQ: ALLR) announced its SPAC, Allarity Acquisition Corp., filed a $100M-$115M IPO registration. ALLR Sponsor LLC, a subsidiary, will own 25% post-offering. The SPAC may pursue deals in any sector. Allarity's working capital is expected to last until mid-2028.
2 min readAllarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when
6 min readAllarity Therapeutics (NASDAQ: ALLR) reported Q2 2026 results and said it ended June 30 with $26.9 million in cash and restricted cash. The company said the USPTO granted a key patent for its stenoparib-specific DRP companion diagnostic through April 2042, and it completed its stenoparib Phase 3-ready manufacturing campaign and obtained CLIA certification for in-house DRP testing.
6 min readAllarity Therapeutics (NASDAQ: ALLR) said it obtained CLIA Certificate of Registration for its in-house laboratory in Horsholm, Denmark, enabling it to run DRP® biomarker testing internally for FDA registration-related studies. The company expects faster turnaround, streamlined trial communication, and lower long-term costs, and may offer CLIA-compliant testing services to partners.
4 min readAllarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001860657 0001860657 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
4 min read
